Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
Journal
Experimental & molecular medicine
ISSN: 2092-6413
Titre abrégé: Exp Mol Med
Pays: United States
ID NLM: 9607880
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
24
11
2023
accepted:
14
04
2024
revised:
18
03
2024
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
30
6
2024
Statut:
aheadofprint
Résumé
Over the past decade, the emergence of patient-derived tumor organoids (PDTOs) has broadened the repertoire of preclinical models and progressively revolutionized three-dimensional cell culture in oncology. PDTO can be grown from patient tumor samples with high efficiency and faithfully recapitulates the histological and molecular characteristics of the original tumor. Therefore, PDTOs can serve as invaluable tools in oncology research, and their translation to clinical practice is exciting for the future of precision medicine in oncology. In this review, we provide an overview of methods for establishing PDTOs and their various applications in cancer research, starting with basic research and ending with the identification of new targets and preclinical validation of new anticancer compounds and precision medicine. Finally, we highlight the challenges associated with the clinical implementation of PDTO, such as its representativeness, success rate, assay speed, and lack of a tumor microenvironment. Technological developments and autologous cocultures of PDTOs and stromal cells are currently ongoing to meet these challenges and optimally exploit the full potential of these models. The use of PDTOs as standard tools in clinical oncology could lead to a new era of precision oncology in the coming decade.
Identifiants
pubmed: 38945959
doi: 10.1038/s12276-024-01272-5
pii: 10.1038/s12276-024-01272-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondation de l'Avenir pour la Recherche Médicale Appliquée (Fondation de l'Avenir)
ID : AP-RM-19-020
Organisme : Fondation ARC pour la Recherche sur le Cancer (ARC Foundation for Cancer Research)
ID : PJA20191209649
Organisme : Fondation ARC pour la Recherche sur le Cancer (ARC Foundation for Cancer Research)
ID : TRANSPARANCE
Organisme : Ligue Contre le Cancer
ID : TRANSPARANCE
Organisme : Ligue Contre le Cancer
ID : ORGAPRED
Organisme : Canceropôle PACA (Canceropole PACA)
ID : 3D-Hub
Organisme : Canceropôle PACA (Canceropole PACA)
ID : 3D-Hub
Organisme : Institut National Du Cancer (French National Cancer Institute)
ID : Pré-néo 2019-188
Informations de copyright
© 2024. The Author(s).
Références
Scherer, W. F., Syverton, J. T. & Gey, G. O. Studies on the propagation in vitro of poliomyelitis viruses. J. Exp. Med. 97, 695–710 (1953).
pubmed: 13052828
pmcid: 2136303
doi: 10.1084/jem.97.5.695
Borrell, B. How accurate are cancer cell lines? Nature 463, 858–858 (2010).
pubmed: 20164888
doi: 10.1038/463858a
Sutherland, R. M., Inch, W. R., McCredie, J. A. & Kruuv, J. A multi-component radiation survival curve using an in vitro tumour model. Int J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 18, 491–495 (1970).
pubmed: 5316564
doi: 10.1080/09553007014551401
Weiswald, L.-B., Bellet, D. & Dangles-Marie, V. Spherical cancer models in tumor biology. Neoplasia 17, 1–15 (2015).
pubmed: 25622895
pmcid: 4309685
doi: 10.1016/j.neo.2014.12.004
Freeman, A. E. & Hoffman, R. M. In vivo-like growth of human tumors in vitro. Proc. Natl Acad. Sci. USA 83, 2694–2698 (1986).
pubmed: 3458228
pmcid: 323366
doi: 10.1073/pnas.83.8.2694
Bjerkvig, R., Tønnesen, A., Laerum, O. D. & Backlund, E. O. Multicellular tumor spheroids from human gliomas maintained in organ culture. J. Neurosurg. 72, 463–475 (1990).
pubmed: 2406382
doi: 10.3171/jns.1990.72.3.0463
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).
pubmed: 12629218
pmcid: 153034
doi: 10.1073/pnas.0530291100
Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821–5828 (2003).
pubmed: 14522905
Weiswald, L.-B. et al. Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. Br. J. Cancer 101, 473–482 (2009).
pubmed: 19603013
pmcid: 2720229
doi: 10.1038/sj.bjc.6605173
Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262–265 (2009).
pubmed: 19329995
doi: 10.1038/nature07935
Kim, J., Koo, B.-K. & Knoblich, J. A. Human organoids: model systems for human biology and medicine. Nat. Rev. Mol. Cell Biol. 21, 571–584 (2020).
pubmed: 32636524
pmcid: 7339799
doi: 10.1038/s41580-020-0259-3
Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011).
pubmed: 21889923
doi: 10.1053/j.gastro.2011.07.050
Foo, M. A. et al. Clinical translation of patient-derived tumour organoids- bottlenecks and strategies. Biomark. Res. 10, 10 (2022).
pubmed: 35272694
pmcid: 8908618
doi: 10.1186/s40364-022-00356-6
Driehuis, E., Kretzschmar, K. & Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380–3409 (2020).
pubmed: 32929210
doi: 10.1038/s41596-020-0379-4
Xu, H. et al. Organoid technology and applications in cancer research. J. Hematol. Oncol. 11, 116 (2018).
pubmed: 30219074
pmcid: 6139148
doi: 10.1186/s13045-018-0662-9
Barbet, V. & Broutier, L. Future Match Making: When Pediatric Oncology Meets Organoid Technology. Front. Cell Dev. Biol. 9, 674219 (2021).
pubmed: 34327198
pmcid: 8315550
doi: 10.3389/fcell.2021.674219
Fan, H., Demirci, U. & Chen, P. Emerging organoid models: leaping forward in cancer research. J. Hematol. Oncol. 12, 142 (2019).
pubmed: 31884964
pmcid: 6936115
doi: 10.1186/s13045-019-0832-4
van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933–945 (2015).
pubmed: 25957691
pmcid: 6428276
doi: 10.1016/j.cell.2015.03.053
Broutier, L. et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat. Med. 23, 1424–1435 (2017).
pubmed: 29131160
pmcid: 5722201
doi: 10.1038/nm.4438
Lee, S. H. et al. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell 173, 515–528.e17 (2018).
pubmed: 29625057
pmcid: 5890941
doi: 10.1016/j.cell.2018.03.017
DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514–1520 (2011).
pubmed: 22019887
pmcid: 3553601
doi: 10.1038/nm.2454
Kopper, O. et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat. Med. 25, 838–849 (2019).
pubmed: 31011202
doi: 10.1038/s41591-019-0422-6
Dolega, M. E., Abeille, F., Picollet-D’hahan, N. & Gidrol, X. Controlled 3D culture in Matrigel microbeads to analyze clonal acinar development. Biomaterials 52, 347–357 (2015).
pubmed: 25818441
doi: 10.1016/j.biomaterials.2015.02.042
Passaniti, A., Kleinman, H. K. & Martin, G. R. Matrigel: history/background, uses, and future applications. J. Cell Commun. Signal 16, 621–626 (2022).
pubmed: 34463918
doi: 10.1007/s12079-021-00643-1
Sachs, N., Tsukamoto, Y., Kujala, P., Peters, P. J. & Clevers, H. Intestinal epithelial organoids fuse to form self-organizing tubes in floating collagen gels. Development 144, 1107–1112 (2017).
pubmed: 28292848
doi: 10.1242/dev.143933
Sokol, E. S. et al. Growth of human breast tissues from patient cells in 3D hydrogel scaffolds. Breast Cancer Res. 18, 19 (2016).
pubmed: 26926363
pmcid: 4772689
doi: 10.1186/s13058-016-0677-5
Capeling, M. M. et al. Nonadhesive Alginate Hydrogels Support Growth of Pluripotent Stem Cell-Derived Intestinal Organoids. Stem Cell Rep. 12, 381–394 (2019).
doi: 10.1016/j.stemcr.2018.12.001
Giobbe, G. G. et al. Extracellular matrix hydrogel derived from decellularized tissues enables endodermal organoid culture. Nat. Commun. 10, 5658 (2019).
pubmed: 31827102
pmcid: 6906306
doi: 10.1038/s41467-019-13605-4
Gjorevski, N. & Lutolf, M. P. Synthesis and characterization of well-defined hydrogel matrices and their application to intestinal stem cell and organoid culture. Nat. Protoc. 12, 2263–2274 (2017).
pubmed: 28981121
doi: 10.1038/nprot.2017.095
Lancaster, M. A. et al. Guided self-organization and cortical plate formation in human brain organoids. Nat. Biotechnol. 35, 659–666 (2017).
pubmed: 28562594
pmcid: 5824977
doi: 10.1038/nbt.3906
Patel, S., Alam, A., Pant, R. & Chattopadhyay, S. Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights. Front. Immunol. 10, 2872 (2019).
pubmed: 31921137
pmcid: 6927425
doi: 10.3389/fimmu.2019.02872
Fujii, M. et al. A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. Cell Stem Cell 18, 827–838 (2016).
pubmed: 27212702
doi: 10.1016/j.stem.2016.04.003
Drost, J. et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521, 43–47 (2015).
pubmed: 25924068
doi: 10.1038/nature14415
Verissimo, C. S. et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. Elife 5, e18489 (2016).
pubmed: 27845624
pmcid: 5127645
doi: 10.7554/eLife.18489
Li, X., Ootani, A. & Kuo, C. An Air-Liquid Interface Culture System for 3D Organoid Culture of Diverse Primary Gastrointestinal Tissues. Methods Mol. Biol. 1422, 33–40 (2016).
pubmed: 27246020
doi: 10.1007/978-1-4939-3603-8_4
Neal, J. T. et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell 175, 1972–1988.e16 (2018).
pubmed: 30550791
pmcid: 6656687
doi: 10.1016/j.cell.2018.11.021
Co, J. Y., Margalef-Català, M., Monack, D. M. & Amieva, M. R. Controlling the polarity of human gastrointestinal organoids to investigate epithelial biology and infectious diseases. Nat. Protoc. 16, 5171–5192 (2021).
pubmed: 34663962
pmcid: 8841224
doi: 10.1038/s41596-021-00607-0
Jacob, F. et al. A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell 180, 188–204.e22 (2020).
pubmed: 31883794
doi: 10.1016/j.cell.2019.11.036
Bürtin, F. et al. Creation and Maintenance of a Living Biobank - How We Do It. J. Vis. Exp. https://doi.org/10.3791/62065 . (2021).
Hoare, O. et al. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. Cancers 13, 2473 (2021).
pubmed: 34069519
pmcid: 8161239
doi: 10.3390/cancers13102473
de Witte, C. J. et al. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses. Cell Rep. 31, 107762 (2020).
pubmed: 32553164
doi: 10.1016/j.celrep.2020.107762
Derouet, M. F. et al. Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor. Sci. Rep. 10, 14514 (2020).
pubmed: 32884042
pmcid: 7471705
doi: 10.1038/s41598-020-71589-4
Ganesh, K. et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat. Med. 25, 1607–1614 (2019).
pubmed: 31591597
pmcid: 7385919
doi: 10.1038/s41591-019-0584-2
Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926 (2018).
pubmed: 29472484
pmcid: 6112415
doi: 10.1126/science.aao2774
Gorski, J. W. et al. Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance. Biomedicines 9, 1021 (2021).
pubmed: 34440225
pmcid: 8394135
doi: 10.3390/biomedicines9081021
Liu, H.-D., Xia, B.-R., Jin, M.-Z. & Lou, G. Organoid of ovarian cancer: genomic analysis and drug screening. Clin. Transl. Oncol. 22, 1240–1251 (2020).
pubmed: 31939100
pmcid: 7316695
doi: 10.1007/s12094-019-02276-8
Becker, L. et al. Data-Driven Identification of Biomarkers for In Situ Monitoring of Drug Treatment in Bladder Cancer Organoids. Int. J. Mol. Sci. 23, 6956 (2022).
pubmed: 35805961
pmcid: 9266781
doi: 10.3390/ijms23136956
Spiller, E. R. et al. Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response. Front. Oncol. 11, 771173 (2021).
pubmed: 34993134
pmcid: 8724556
doi: 10.3389/fonc.2021.771173
Sharick, J. T. et al. Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Front. Oncol. 10, 553 (2020).
pubmed: 32500020
pmcid: 7242740
doi: 10.3389/fonc.2020.00553
Neef, S. K. et al. Metabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS. Metabolites 10, 494 (2020).
pubmed: 33271860
pmcid: 7760698
doi: 10.3390/metabo10120494
Yao, Y. et al. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Stem Cell 26, 17–26.e6 (2020).
pubmed: 31761724
doi: 10.1016/j.stem.2019.10.010
Larsen, B. M. et al. A pan-cancer organoid platform for precision medicine. Cell Rep. 36, 109429 (2021).
pubmed: 34320344
doi: 10.1016/j.celrep.2021.109429
Scognamiglio, G. et al. Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. Br. J. Cancer 121, 979–982 (2019).
pubmed: 31666667
pmcid: 6889147
doi: 10.1038/s41416-019-0616-1
Dekkers, J. F. et al. Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids. J. Natl Cancer Inst. 112, 540–544 (2020).
pubmed: 31589320
doi: 10.1093/jnci/djz196
Seino, T. et al. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. Cell Stem Cell 22, 454–467.e6 (2018).
pubmed: 29337182
doi: 10.1016/j.stem.2017.12.009
Hu, T. et al. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. Gastroenterology 161, 1584–1600 (2021).
pubmed: 34245764
doi: 10.1053/j.gastro.2021.06.045
Li, F. et al. Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data. EBioMedicine 69, 103436 (2021).
pubmed: 34157484
pmcid: 8220577
doi: 10.1016/j.ebiom.2021.103436
Picollet-D’hahan, N., Dolega, M. E., Freida, D., Martin, D. K. & Gidrol, X. Deciphering Cell Intrinsic Properties: A Key Issue for Robust Organoid Production. Trends Biotechnol. 35, 1035–1048 (2017).
pubmed: 28927991
doi: 10.1016/j.tibtech.2017.08.003
Guillon, J. et al. Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity. Cell Cycle 18, 2385–2397 (2019).
pubmed: 31397193
pmcid: 6738909
doi: 10.1080/15384101.2019.1652047
Germain, N. et al. Lipid Metabolism and Resistance to Anticancer Treatment. Biology 9, 474 (2020).
pubmed: 33339398
pmcid: 7766644
doi: 10.3390/biology9120474
Strauss, J. & Figg, W. D. Epigenetic approaches to overcoming chemotherapy resistance. Lancet Oncol. 16, 1013–1015 (2015).
pubmed: 26296953
pmcid: 6387683
doi: 10.1016/S1470-2045(15)00231-4
El Amrani, M. et al. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. Mol. Carcinog. 58, 1985–1997 (2019).
pubmed: 31373074
doi: 10.1002/mc.23090
Fernandes, M., Jamme, P., Cortot, A. B., Kherrouche, Z. & Tulasne, D. When the MET receptor kicks in to resist targeted therapies. Oncogene 40, 4061–4078 (2021).
pubmed: 34031544
doi: 10.1038/s41388-021-01835-0
Sundar, S. J. et al. Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma. Transl. Oncol. 15, 101251 (2021).
pubmed: 34700192
pmcid: 8551697
doi: 10.1016/j.tranon.2021.101251
Farshadi, E. A. et al. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 27, 6602–6612 (2021).
pubmed: 34580113
pmcid: 9401459
doi: 10.1158/1078-0432.CCR-21-1681
Huang, L. et al. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI Insight 5, e135544 (2020).
pubmed: 32990680
pmcid: 7710298
doi: 10.1172/jci.insight.135544
Hadj Bachir, E. et al. A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms. Biol. Cell 114, 32–55 (2022).
pubmed: 34561874
doi: 10.1111/boc.202100003
Driehuis, E. et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc. Natl Acad. Sci. 116, 26580–26590 (2019).
pubmed: 31818951
pmcid: 6936689
doi: 10.1073/pnas.1911273116
Tan, P. et al. SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. Oncogene 40, 6081–6092 (2021).
pubmed: 34471236
doi: 10.1038/s41388-021-01999-9
Yan, H. H. N. et al. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. Cell Stem Cell 23, 882–897.e11 (2018).
pubmed: 30344100
doi: 10.1016/j.stem.2018.09.016
Sachs, N. et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell 172, 373–386.e10 (2018).
pubmed: 29224780
doi: 10.1016/j.cell.2017.11.010
Calandrini, C. et al. Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Rep. 36, 109568 (2021).
pubmed: 34433038
doi: 10.1016/j.celrep.2021.109568
Vernon, M. et al. Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids. Mol. Cancer Therapeutics 19, 1506–1519 (2020).
doi: 10.1158/1535-7163.MCT-19-0510
Florent, R. et al. Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib. Cell Death Dis. 11, 1–16 (2020).
doi: 10.1038/s41419-020-2588-8
Wambecke, A. et al. The lncRNA ‘UCA1’ modulates the response to chemotherapy of ovarian cancer through direct binding to miR‐27a‐5p and control of UBE2N levels. Mol. Oncol. 15, 3659–3678 (2021).
pubmed: 34160887
pmcid: 8637575
doi: 10.1002/1878-0261.13045
Garvey, C. M. et al. Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance. Cancers 12, 1393 (2020).
pubmed: 32481658
pmcid: 7352975
doi: 10.3390/cancers12061393
Millen, R. et al. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification. Medicine 4, 290–310.e12 (2023).
doi: 10.1016/j.medj.2023.04.003
Chen, G. et al. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution. Cell Oncol. 45, 1155–1167 (2022).
doi: 10.1007/s13402-022-00728-y
Shi, X. et al. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Nat. Commun. 13, 2169 (2022).
pubmed: 35449156
pmcid: 9023604
doi: 10.1038/s41467-022-29857-6
Braun, L. M. et al. Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures. Cancers 12, 1440 (2020).
pubmed: 32492856
pmcid: 7352957
doi: 10.3390/cancers12061440
Kong, J. et al. Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. Nat. Commun. 11, 5485 (2020).
pubmed: 33127883
pmcid: 7599252
doi: 10.1038/s41467-020-19313-8
Ancevski Hunter, K., Socinski, M. A. & Villaruz, L. C. PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol. Diagn. Ther. 22, 1–10 (2018).
pubmed: 29119407
doi: 10.1007/s40291-017-0308-6
Bailey, M. H. et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173, 371–385.e18 (2018).
pubmed: 29625053
pmcid: 6029450
doi: 10.1016/j.cell.2018.02.060
Letai, A., Bhola, P. & Welm, A. L. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40, 26–35 (2022).
pubmed: 34951956
doi: 10.1016/j.ccell.2021.12.004
Mirza, M. R. et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N. Engl. J. Med. 375, 2154–2164 (2016).
pubmed: 27717299
doi: 10.1056/NEJMoa1611310
Federici, G. & Soddu, S. Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. J. Exp. Clin. Cancer Res. 39, 46 (2020).
pubmed: 32127026
pmcid: 7055088
doi: 10.1186/s13046-020-01554-6
Nicolle, R. et al. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer. Transl. Oncol. 16, 101315 (2022).
pubmed: 34906890
doi: 10.1016/j.tranon.2021.101315
Verduin, M., Hoeben, A., De Ruysscher, D. & Vooijs, M. Patient-Derived Cancer Organoids as Predictors of Treatment Response. Front. Oncol. 11, 641980 (2021).
pubmed: 33816288
pmcid: 8012903
doi: 10.3389/fonc.2021.641980
Wensink, G. E. et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. NPJ Precis Oncol. 5, 30 (2021).
pubmed: 33846504
pmcid: 8042051
doi: 10.1038/s41698-021-00168-1
Tsukamoto, Y. et al. Enhanced phosphorylation of c-Jun by cisplatin treatment as a potential predictive biomarker for cisplatin response in combination with patient-derived tumor organoids. Lab. Invest. 102, 1355–1366 (2022).
pubmed: 35922477
doi: 10.1038/s41374-022-00827-2
Beutel, A. K. et al. A Prospective Feasibility Trial to Challenge Patient–Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Cancers 13, 2539 (2021).
pubmed: 34064221
pmcid: 8196829
doi: 10.3390/cancers13112539
Park, M. et al. A Patient-Derived Organoid-Based Radiosensitivity Model for the Prediction of Radiation Responses in Patients with Rectal Cancer. Cancers 13, 3760 (2021).
pubmed: 34359661
pmcid: 8345202
doi: 10.3390/cancers13153760
Driehuis, E. et al. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discov. 9, 852–871 (2019).
pubmed: 31053628
doi: 10.1158/2159-8290.CD-18-1522
Hill, S. J. et al. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 8, 1404–1421 (2018).
pubmed: 30213835
pmcid: 6365285
doi: 10.1158/2159-8290.CD-18-0474
Mauri, G. et al. Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. JCO Precis. Oncol. 5, PO.21.00143 (2021).
pubmed: 34327296
pmcid: 8315302
Buyse, M. et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J. Clin. Oncol. 25, 5218–5224 (2007).
Ooft, S. N. et al. (2019) Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients Dishing out treatment recommendations. Sci. Transl. Med. 11, eaay2574 (2019).
Ooft, S. N. et al. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open 6, 100103 (2021).
pubmed: 33887686
pmcid: 8086019
doi: 10.1016/j.esmoop.2021.100103
Liu, Y. et al. Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer. J. Oncol. 2022, 9390912 (2022).
pubmed: 36046364
pmcid: 9423951
Tiriac, H. et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 8, 1112–1129 (2018).
pubmed: 29853643
pmcid: 6125219
doi: 10.1158/2159-8290.CD-18-0349
Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176–187 (2014).
pubmed: 25201530
pmcid: 4237931
doi: 10.1016/j.cell.2014.08.016
Kim, M. et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat. Commun. 10, 3991 (2019).
pubmed: 31488816
pmcid: 6728380
doi: 10.1038/s41467-019-11867-6
Dijkstra, K. K. et al. Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine. Cell Rep. 31, 107588 (2020).
pubmed: 32375033
doi: 10.1016/j.celrep.2020.107588
Wallaschek, N. et al. Establishing Pure Cancer Organoid Cultures: Identification, Selection and Verification of Cancer Phenotypes and Genotypes. J. Mol. Biol. 431, 2884–2893 (2019).
pubmed: 31150736
doi: 10.1016/j.jmb.2019.05.031
Colella, G. et al. Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine. Int J. Mol. Sci. 19, 615 (2018).
pubmed: 29466296
pmcid: 5855837
doi: 10.3390/ijms19020615
Majumder, B. et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat. Commun. 6, 6169 (2015).
pubmed: 25721094
doi: 10.1038/ncomms7169
Heo, J. H., Kang, D., Seo, S. J. & Jin, Y. Engineering the Extracellular Matrix for Organoid Culture. Int J. Stem Cells 15, 60–69 (2022).
pubmed: 35220292
pmcid: 8889330
doi: 10.15283/ijsc21190
Xie, Z., Wang, L. & Zhang, Y. Advances in Organoid Culture Research. Glob. Med. Genet 9, 268–276 (2022).
pubmed: 36530528
pmcid: 9750796
doi: 10.1055/s-0042-1756662
Hu, Y. et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat. Commun. 12, 2581 (2021).
pubmed: 33972544
pmcid: 8110811
doi: 10.1038/s41467-021-22676-1
Ding, S. et al. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell 29, 905–917.e6 (2022).
pubmed: 35508177
pmcid: 9177814
doi: 10.1016/j.stem.2022.04.006
Phan, N. et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun. Biol. 2, 78 (2019).
pubmed: 30820473
pmcid: 6389967
doi: 10.1038/s42003-019-0305-x
Kim, S. K., Kim, Y. H., Park, S. & Cho, S.-W. Organoid engineering with microfluidics and biomaterials for liver, lung disease, and cancer modeling. Acta Biomater. 132, 37–51 (2021).
pubmed: 33711526
doi: 10.1016/j.actbio.2021.03.002
Larsen, B. M., Cancino, A., Shaxted, J. M. & Salahudeen, A. A. Protocol for drug screening of patient-derived tumor organoids using high-content fluorescent imaging. STAR Protoc. 3, 101407 (2022).
pubmed: 35620075
pmcid: 9127194
doi: 10.1016/j.xpro.2022.101407
Brandenberg, N. et al. High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays. Nat. Biomed. Eng. 4, 863–874 (2020).
pubmed: 32514094
doi: 10.1038/s41551-020-0565-2
Wang, J. et al. Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy. Front. Oncol. 12, 872531 (2022).
pubmed: 35449581
pmcid: 9016336
doi: 10.3389/fonc.2022.872531
Liu, L., Yu, L., Li, Z., Li, W. & Huang, W. Patient-derived organoid (PDO) platforms to facilitate clinical decision making. J. Transl. Med. 19, 40 (2021).
pubmed: 33478472
pmcid: 7821720
doi: 10.1186/s12967-020-02677-2
Qu, J., Kalyani, F. S., Liu, L., Cheng, T. & Chen, L. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun. 41, 1331–1353 (2021).
doi: 10.1002/cac2.12224
Fan, T. W. et al. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues. Elife 10, e69578 (2021).
pubmed: 34406120
pmcid: 8476122
doi: 10.7554/eLife.69578
Martin, S. Z. et al. Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. BMC Cancer 19, 1030 (2019).
pubmed: 31675944
pmcid: 6824140
doi: 10.1186/s12885-019-6270-4
Saleh, R., Toor, S. M., Al-Ali, D., Sasidharan Nair, V. & Elkord, E. Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. Genes 11, 703 (2020).
pubmed: 32616706
pmcid: 7349021
doi: 10.3390/genes11060703
Wan, C. et al. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 81, 158–173 (2021).
pubmed: 33158814
doi: 10.1158/0008-5472.CAN-20-1674
Ao, Z. et al. Rapid Profiling of Tumor-Immune Interaction Using Acoustically Assembled Patient-Derived Cell Clusters. Adv. Sci. 9, e2201478 (2022).
doi: 10.1002/advs.202201478
Knochelmann, H. M. et al. Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. Oncoimmunology 10, 1959101 (2021).
pubmed: 34408920
pmcid: 8366547
doi: 10.1080/2162402X.2021.1959101
Bonnereau, J. et al. Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition. Gut 72, 699–709 (2023).
pubmed: 35803702
doi: 10.1136/gutjnl-2021-326553
Hammoudi, N. et al. Autologous organoid co-culture model reveals T cell-driven epithelial cell death in Crohn’s Disease. Front. Immunol. 13, 1008456 (2022).
pubmed: 36439157
pmcid: 9685428
doi: 10.3389/fimmu.2022.1008456
Kong, J. C. H. et al. Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. JCO Precis. Oncol. 2, 1–15 (2018).
pubmed: 35135158
doi: 10.1200/PO.18.00075
Nozaki, K. et al. Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J. Gastroenterol. 51, 206–213 (2016).
pubmed: 26800996
pmcid: 4771822
doi: 10.1007/s00535-016-1170-8
Votanopoulos, K. I. et al. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. Ann. Surg. Oncol. 27, 1956–1967 (2020).
pubmed: 31858299
doi: 10.1245/s10434-019-08143-8
Forsythe, S. D. et al. Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study. Clin. Cancer Res. 27, 5141–5150 (2021).
pubmed: 34210684
pmcid: 8720262
doi: 10.1158/1078-0432.CCR-21-0982
Forsythe, S. D. et al. Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research. Sci. Rep. 12, 13865 (2022).
pubmed: 35974123
pmcid: 9380677
doi: 10.1038/s41598-022-17921-6
Holokai, L. et al. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Cancers 12, 3816 (2020).
pubmed: 33348809
pmcid: 7766822
doi: 10.3390/cancers12123816
Tsai, S. et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer 18, 335 (2018).
pubmed: 29587663
pmcid: 5870823
doi: 10.1186/s12885-018-4238-4
Dijkstra, K. K. et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell 174, 1586–1598.e12 (2018).
pubmed: 30100188
pmcid: 6558289
doi: 10.1016/j.cell.2018.07.009
Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).
pubmed: 32251400
doi: 10.1038/s41591-020-0805-8
Cattaneo, C. M. et al. Tumor organoid-T-cell coculture systems. Nat. Protoc. 15, 15–39 (2020).
pubmed: 31853056
doi: 10.1038/s41596-019-0232-9
Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell 185, 4049–4066.e25 (2022).
pubmed: 36208623
doi: 10.1016/j.cell.2022.09.020
Clinton, J. & McWilliams-Koeppen, P. Initiation, Expansion, and Cryopreservation of Human Primary Tissue-Derived Normal and Diseased Organoids in Embedded Three-Dimensional Culture. Curr. Protoc. Cell Biol. 82, e66 (2019).
pubmed: 30265443
doi: 10.1002/cpcb.66
Zhao, H., Jiang, E. & Shang, Z. 3D Co-culture of Cancer-Associated Fibroblast with Oral Cancer Organoids. J. Dent. Res. 100, 201–208 (2021).
pubmed: 32881601
doi: 10.1177/0022034520956614
Chen, X. et al. Phenotype transition of fibroblasts incorporated into patient-derived oral carcinoma organoids. Oral. Dis. 29, 913–922 (2023).
pubmed: 34741375
doi: 10.1111/odi.14071
Öhlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
pubmed: 28232471
pmcid: 5339682
doi: 10.1084/jem.20162024
Chen, S. et al. Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture. Proc. Natl Acad. Sci. USA 115, E11671–E11680 (2018).
pubmed: 30487219
pmcid: 6294935
doi: 10.1073/pnas.1803718115
Liu, J. et al. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance. Cell Mol. Gastroenterol. Hepatol. 11, 407–431 (2021).
pubmed: 32932015
doi: 10.1016/j.jcmgh.2020.09.003
Truelsen, S. L. B. et al. The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids. PLoS One 16, e0253258 (2021).
pubmed: 34234354
pmcid: 8263287
doi: 10.1371/journal.pone.0253258
Arslan, U. et al. Vascularized hiPSC-derived 3D cardiac microtissue on chip. Stem Cell Rep. 18, 1394–1404 (2023).
doi: 10.1016/j.stemcr.2023.06.001
Nashimoto, Y. et al. Vascularized cancer on a chip: The effect of perfusion on growth and drug delivery of tumor spheroid. Biomaterials 229, 119547 (2020).
pubmed: 31710953
doi: 10.1016/j.biomaterials.2019.119547
Quintard, C. et al. A microfluidic platform integrating functional vascularized organoids-on-chip. Nat. Commun. 15, 1452 (2024).
pubmed: 38365780
pmcid: 10873332
doi: 10.1038/s41467-024-45710-4
Hachey, S. J. et al. An in vitro vascularized micro-tumor model of human colorectal cancer recapitulates in vivo responses to standard-of-care therapy. Lab a Chip 21, 1333–1351 (2021).
doi: 10.1039/D0LC01216E
Ugrinic, M. et al. Fabrication of high aspect ratio microfluidic devices for long term in vitro culture of 3D tumor models. Microelectronic Eng. 267–268, 111898 (2023).
Haque, M. R. et al. Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment. Microsyst. Nanoeng. 8, 36 (2022).
pubmed: 35450328
pmcid: 8971446
doi: 10.1038/s41378-022-00370-6
Russell, T. et al. Cortical spheroid on perfusable microvascular network in a microfluidic device. Plos One 18, 1–14 (2023).
doi: 10.1371/journal.pone.0288025
Geyer, M. et al. A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. Cell Death Discov. 9, 20 (2023).
pubmed: 36681673
pmcid: 9867742
doi: 10.1038/s41420-023-01334-z
Lee, S.-R. et al. U-IMPACT: a universal 3D microfluidic cell culture platform. Microsyst. Nanoeng. 8, 126 (2022).
pubmed: 36478874
pmcid: 9719897
doi: 10.1038/s41378-022-00431-w
Cai, H. et al. Trapping cell spheroids and organoids using digital acoustofluidics. Biofabrication 12, 035025 (2020).
pubmed: 32438350
doi: 10.1088/1758-5090/ab9582
Quintard, C. et al. Microfluidic device integrating a network of hyper-elastic valves for automated glucose stimulation and insulin secretion collection from a single pancreatic islet. Biosens. Bioelectron. 202, 113967 (2022).
pubmed: 35065480
doi: 10.1016/j.bios.2022.113967
Wang, X. et al. A Tumor‐Organoid‐Based Precision Medicine Platform for the Prediction of Drug Sensitivity of Colorectal Cancer. Adv. Therapeutics 5, 2200093 (2022).
Schuster, B. et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat. Commun. 11, 5271 (2020).
pubmed: 33077832
pmcid: 7573629
doi: 10.1038/s41467-020-19058-4
Pinho, D., Santos, D., Vila, A. & Carvalho, S. Establishment of colorectal cancer organoids in microfluidic-based system. Micromachines 12, 497 (2021).
Cavarzerani, E., Caligiuri, I., Bartoletti, M., Canzonieri, V. & Rizzolio, F. 3D dynamic cultures of HGSOC organoids to model innovative and standard therapies. Front. Bioeng. Biotechnol. 11, 1–13 (2023).
doi: 10.3389/fbioe.2023.1135374
Hachey, S. J. et al. A human vascularized microtumor model of patient-derived colorectal cancer recapitulates clinical disease. Transl. Res. 255, 97–108 (2023).
Rajasekar, S. et al. IFlowPlate—A Customized 384‐Well Plate for the Culture of Perfusable Vascularized Colon Organoids. Adva. Mater. 32, e2002974 (2020).
Palikuqi, B. et al. Adaptable haemodynamic endothelial cells for organogenesis and tumorigenesis. Nature 585, 426–432 (2020).
pubmed: 32908310
pmcid: 7480005
doi: 10.1038/s41586-020-2712-z
Kroll, K. T. et al. Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies. Proc. Natl Acad. Sci. 120, 2017 (2023).
doi: 10.1073/pnas.2305322120
Bussooa, A. et al. Real-time monitoring of oxygen levels within thermoplastic Organ-on-Chip devices. Biosens. Bioelectron. X 11, 4–11 (2022).
Dornhof, J. et al. Microfluidic organ-on-chip system for multi-analyte monitoring of metabolites in 3D cell cultures. Lab Chip 22, 225–239 (2022).
pubmed: 34851349
doi: 10.1039/D1LC00689D
Votanopoulos, K. I. et al. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study. Ann. Surg. Oncol. 26, 139–147 (2019).
pubmed: 30414038
doi: 10.1245/s10434-018-7008-2
Saito, Y. et al. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma. Cell Rep. 27, 1265–1276.e4 (2019).
pubmed: 31018139
doi: 10.1016/j.celrep.2019.03.088
Wang, Z. et al. Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids. Cancer Cell Int. 21, 519 (2021).
pubmed: 34600546
pmcid: 8487492
doi: 10.1186/s12935-021-02219-w
Schütte, M. et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat. Commun. 8, 14262 (2017).
pubmed: 28186126
pmcid: 5309787
doi: 10.1038/ncomms14262
Buzzelli, J. N., Ouaret, D., Brown, G., Allen, P. D. & Muschel, R. J. Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance. Stem Cell Res. 27, 109–120 (2018).
pubmed: 29414601
pmcid: 5842239
doi: 10.1016/j.scr.2018.01.016
Narasimhan, V. et al. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clin. Cancer Res. 26, 3662–3670 (2020).
pubmed: 32376656
pmcid: 8366292
doi: 10.1158/1078-0432.CCR-20-0073
Nanki, K. et al. Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis. Cell 174, 856–869.e17 (2018).
pubmed: 30096312
doi: 10.1016/j.cell.2018.07.027
Li, J. et al. Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening. J. Cancer Res. Clin. Oncol. 145, 2637–2647 (2019).
pubmed: 31598791
doi: 10.1007/s00432-019-03004-z
Kawasaki, K. et al. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Cell 183, 1420–1435.e21 (2020).
pubmed: 33159857
doi: 10.1016/j.cell.2020.10.023
D’Agosto, S. et al. Long-term organoid culture of a small intestinal neuroendocrine tumor. Front. Endocrinol. 14, 999792 (2023).
doi: 10.3389/fendo.2023.999792
Dijkstra, K. K. et al. Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma. Front. Endocrinol. 12, 627819 (2021).
doi: 10.3389/fendo.2021.627819
Nuciforo, S. et al. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Rep. 24, 1363–1376 (2018).
pubmed: 30067989
pmcid: 6088153
doi: 10.1016/j.celrep.2018.07.001
Beato, F. et al. Establishing a Living Biobank of Patient-Derived Organoids of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Lab. Invest. 101, 204–217 (2021).
pubmed: 33037322
doi: 10.1038/s41374-020-00494-1
Mazzucchelli, S. et al. Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer. Biol. Proced. Online 21, 12 (2019).
pubmed: 31223292
pmcid: 6570967
doi: 10.1186/s12575-019-0099-8
Maru, Y., Tanaka, N., Itami, M. & Hippo, Y. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol. Oncol. 154, 189–198 (2019).
pubmed: 31101504
doi: 10.1016/j.ygyno.2019.05.005
Boretto, M. et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat. Cell Biol. 21, 1041–1051 (2019).
pubmed: 31371824
doi: 10.1038/s41556-019-0360-z
Tanaka, N. et al. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity. Oral. Oncol. 87, 49–57 (2018).
pubmed: 30527243
pmcid: 6294331
doi: 10.1016/j.oraloncology.2018.10.018
Kijima, T. et al. Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. Cell Mol. Gastroenterol. Hepatol. 7, 73–91 (2019).
pubmed: 30510992
doi: 10.1016/j.jcmgh.2018.09.003
Karakasheva, T. A. et al. Generation and characterization of patient-derived esophageal cancer organoids. Curr. Protoc. Stem Cell Biol. 53, e109 (2020).
pubmed: 32294323
pmcid: 7350550
doi: 10.1002/cpsc.109
Li, X. et al. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nat. Commun. 9, 2983 (2018).
pubmed: 30061675
pmcid: 6065407
doi: 10.1038/s41467-018-05190-9
Wang, B. et al. An organoid library of salivary gland tumors reveals subtype-specific characteristics and biomarkers. J. Exp. Clin. Cancer Res. 41, 350 (2022).
pubmed: 36527158
pmcid: 9758872
doi: 10.1186/s13046-022-02561-5
Lassche, G. et al. Development and characterization of patient-derived salivary gland cancer organoid cultures. Oral. Oncol. 135, 106186 (2022).
pubmed: 36265373
doi: 10.1016/j.oraloncology.2022.106186
Sondorp, L. H. J. et al. Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening. Cancers 12, 3212 (2020).
pubmed: 33142750
pmcid: 7692469
doi: 10.3390/cancers12113212
Yang, H. et al. Establishment of papillary thyroid cancer organoid lines from clinical specimens. Front. Endocrinol. 14, 1140888 (2023).
doi: 10.3389/fendo.2023.1140888
Jiang, Y. et al. Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy. Curr. Urol. 17, 221–228 (2023).
pubmed: 37994334
pmcid: 10662868
doi: 10.1097/CU9.0000000000000219
Bolck, H. A. et al. Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma. Eur. Urol. Focus 7, 152–162 (2021).
pubmed: 31266731
doi: 10.1016/j.euf.2019.06.009
Li, Z. et al. Patient‐derived renal cell carcinoma organoids for personalized cancer therapy. Clin. Transl. Med. 12, e970 (2022).
pubmed: 35802820
pmcid: 9270001
doi: 10.1002/ctm2.970
Puca, L. et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat. Commun. 9, 2404 (2018).
pubmed: 29921838
pmcid: 6008438
doi: 10.1038/s41467-018-04495-z
Verduin, M. et al. Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity. Neuro Oncol. Adv. 5, vdad152 (2023).
Sachs, N. et al. Long-term expanding human airway organoids for disease modeling. EMBO J. 38, e100300 (2019).
pubmed: 30643021
pmcid: 6376275
doi: 10.15252/embj.2018100300
Mazzocchi, A. R., Rajan, S. A. P., Votanopoulos, K. I., Hall, A. R. & Skardal, A. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci. Rep. 8, 2886 (2018).
pubmed: 29440675
pmcid: 5811529
doi: 10.1038/s41598-018-21200-8
Fang, X. et al. Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. Mol. Cancer 23, 12 (2024).
pubmed: 38200517
pmcid: 10782772
doi: 10.1186/s12943-023-01901-z
Ou, L. et al. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine 92, 104614 (2023).
pubmed: 37229906
pmcid: 10277922
doi: 10.1016/j.ebiom.2023.104614
Sun, L. et al. A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options. Sci. Adv. 9, eadg6686 (2023).
pubmed: 37889972
pmcid: 10610903
doi: 10.1126/sciadv.adg6686
Thorel, L. et al. Patient-derived tumor organoids (or tumoroid), a growing preclinical model for oncology. Med. Sci. (Paris) 38, 880–887 (2022).
Perréard, M. et al. Patient-derived tumor organoids (or tumoroid) as valuable precision medicine tools. Med. Sci. (Paris) 38, 888–895 (2022).